Merck KGaA Plays Down Mavenclad Label And $99,500 annual Price For 10 MS Pills

 
• By Sten Stovall
  
Brain
FDA Approved Merck Group's oral Mavenclad in RRMS and active SPMS. • Source: Shutterstock

More from New Products

More from Scrip